Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles

Open access
Tijms, Betty M., Vromen, Ellen M., Mjaavatten, Olav, Holstege, Henne, Reus, Lianne M., van der Lee, Sven, Wesenhagen, Kirsten E. J., Lorenzini, Luigi, Vermunt, Lisa, Venkatraghavan, Vikram, Tesi, Niccoló, Tomassen, Jori, den Braber, Anouk, Goossens, Julie, Vanmechelen, Eugeen, Barkhof, Frederik, Pijnenburg, Yolande A. L., van der Flier, Wiesje M., Teunissen, Charlotte E., Berven, Frode S., Visser, Pieter Jelle · 2024 · Nature Aging

Abstract

Alzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD (n = 419) compared to controls (n = 187). These AD subtypes had alterations in protein levels that were associated with distinct molecular processes: subtype 1 was characterized by proteins related to neuronal hyperplasticity; subtype 2 by innate immune activation; subtype 3 by RNA dysregulation; subtype 4 by choroid plexus dysfunction; and subtype 5 by blood–brain barrier impairment. Each subtype was related to specific AD genetic risk variants, for example, subtype 1 was enriched with TREM2 R47H. Subtypes also differed in clinical outcomes, survival times and anatomical patterns of brain atrophy. These results indicate molecular heterogeneity in AD and highlight the need for personalized medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43587-023-00550-7

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 60 references

Research works printed but not linked: 57

  1. Hondius, D. C. et al. Profiling the human hippocampal proteome at all pathologic stages of Alzheimer’s disease. Alzheimers Dement. 12, 654–668 (2016). · DOI · Paper page
  2. Caldwell, A. B. et al. Transcriptomic profiling of sporadic Alzheimer’s disease patients. Mol. Brain 15, 83 (2022). · DOI
  3. Tijms, B. M. et al. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. Brain 143, 3776–3792 (2020). · DOI · Paper page
  4. Haeberlein, S. B. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 9, 197–210 (2022).
  5. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2022). · DOI · Paper page
  6. Visser, P. J. et al. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease. Mol. Neurodegener. 17, 27 (2022). · DOI
  7. Tijms, B. M. et al. CSF proteomic Alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals. Proteomes 9, 36 (2021). · DOI
  8. van der Flier, W. M. et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J. Alzheimers Dis. 41, 313–327 (2014). · DOI · Paper page
  9. Konijnenberg, E. et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res. Ther. 10, 85 (2018). · DOI
  10. Legdeur, N. et al. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr. 18, 289 (2018). · DOI
  11. Ritchie, C. W. et al. The European Prevention of Alzheimer’s Dementia (EPAD) longitudinal cohort study: baseline data release V500.0. J. Prev. Alzheimers Dis. 7, 8–13 (2020).
  12. de Leon, M. J. et al. The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer’s disease. PLoS ONE 13, e0191240 (2018). · DOI
  13. Lee, D. D. & Seung, H. S. Learning the parts of objects by non-negative matrix factorization. Nature 401, 788–791 (1999). · DOI · Paper page
  14. Karch, C. M., Jeng, A. T. & Goate, A. M. Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J. Biol. Chem. 287, 42751–42762 (2012). · DOI · Paper page
  15. Yamada, K. et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387–393 (2014). · DOI · Paper page
  16. Kaeser, S. A. et al. CSF p-tau increase in response to Aβ-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 143, 287–290 (2022). · DOI
  17. Ballas, N. & Mandel, G. The many faces of REST oversee epigenetic programming of neuronal genes. Curr. Opin. Neurobiol. 15, 500–506 (2005). · DOI · Paper page
  18. Lu, T. et al. REST and stress resistance in ageing and Alzheimer’s disease. Nature 507, 448–454 (2014). · DOI · Paper page
  19. Sadleir, K. R. et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease. Acta Neuropathol. 132, 235–256 (2016). · DOI · Paper page
  20. Cosker, K. et al. Microglial signalling pathway deficits associated with the patient derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome. Sci. Rep. 11, 13316 (2021). · DOI
  21. Zhao, R., Hu, W., Tsai, J., Li, W. & Gan, W.-B. Microglia limit the expansion of β-amyloid plaques in a mouse model of Alzheimer’s disease. Mol. Neurodegener. 12, 47 (2017). · DOI · Paper page
  22. Yuan, P. et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90, 724–739 (2016). · DOI · Paper page
  23. Stoiljkovic, M., Gutierrez, K. O., Kelley, C., Horvath, T. L. & Hajós, M. TREM2 deficiency disrupts network oscillations leading to epileptic activity and aggravates amyloid-β-related hippocampal pathophysiology in mice. J. Alzheimers Dis. 88, 837–847 (2022). · DOI
  24. Hu, B. et al. Insights into the role of CSF1R in the central nervous system and neurological disorders. Front. Aging Neurosci. 13, 789834 (2021). · DOI
  25. Tábuas-Pereira, M., Santana, I., Guerreiro, R. & Brás, J. Alzheimer’s disease genetics: review of novel loci associated with disease. Curr. Genet. Med. Rep. 8, 1–16 (2020). · DOI
  26. Geuens, T., Bouhy, D. & Timmerman, V. The hnRNP family: insights into their role in health and disease. Hum. Genet. 135, 851–867 (2016). · DOI · Paper page
  27. Kavanagh, T., Halder, A. & Drummond, E. Tau interactome and RNA binding proteins in neurodegenerative diseases. Mol. Neurodegener. 17, 66 (2022). · DOI · Paper page
  28. Sidhu, R., Gatt, A., Fratta, P., Lashley, T. & Bampton, A. HnRNP K mislocalisation in neurons of the dentate nucleus is a novel neuropathological feature of neurodegenerative disease and ageing. Neuropath. Appl. Neurobiol. 48, e12793 (2022). · DOI
  29. Yu, Q.-S., Feng, W.-Q., Shi, L.-L., Niu, R.-Z. & Liu, J. Integrated analysis of cortex single-cell transcriptome and serum proteome reveals the novel biomarkers in Alzheimer’s disease. Brain Sci. 12, 1022 (2022). · DOI
  30. Moore, D. L. et al. KLF family members regulate intrinsic axon regeneration ability. Science 326, 298–301 (2009). · DOI · Paper page
  31. Wei, Y. et al. Multiple direct interactions of TBP with the MYC oncoprotein. Nat. Struct. Mol. Biol. 26, 1035–1043 (2019). · DOI
  32. Majd, S., Power, J. & Majd, Z. Alzheimer’s disease and cancer: when two monsters cannot be together. Front. Neurosci. 13, 155 (2019). · DOI
  33. Tan, M.-S., Yu, J.-T. & Tan, L. Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. Trends Mol. Med. 19, 594–603 (2013). · DOI · Paper page
  34. Damián-Zamacona, S. et al. Cell survival regulation during receptor-mediated endocytosis of chemically-modified lipoproteins associated to the formation of an Amphiphysin 2 (Bin1)/c-Myc complex. Biochem. Bioph. Res. Commun. 505, 365–371 (2018). · DOI
  35. Mehta, P. R., Brown, A.-L., Ward, M. E. & Fratta, P. The era of cryptic exons: implications for ALS-FTD. Mol. Neurodegener. 18, 16 (2023). · DOI
  36. Liddelow, S. A. Development of the choroid plexus and blood–CSF barrier. Front. Neurosci. 9, 32 (2015). · DOI · Paper page
  37. Serot, J.-M., Béné, M.-C., Foliguet, B. & Faure, G. C. Morphological alterations of the choroid plexus in late-onset Alzheimer’s disease. Acta Neuropathol. 99, 105–108 (2000). · DOI · Paper page
  38. Čarna, M. et al. Pathogenesis of Alzheimer’s disease: involvement of the choroid plexus. Alzheimers Dement. 19, 3537–3554 (2023). · DOI
  39. Cui, J. et al. Inflammation of the embryonic choroid plexus barrier following maternal immune activation. Dev. Cell 55, 617–628 (2020). · DOI · Paper page
  40. Bossaerts, L., Cacace, R. & Van Broeckhoven, C. The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease. Mol. Neurodegener. 17, 31 (2022). · DOI
  41. Chitu, V., Gokhan, Ş., Nandi, S., Mehler, M. F. & Stanley, E. R. Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends Neurosci. 39, 378–393 (2016). · DOI · Paper page
  42. Zuroff, L. R. et al. Effects of IL-34 on macrophage immunological profile in response to Alzheimer’s-related Aβ42 assemblies. Front. Immunol. 11, 1449 (2020). · DOI
  43. Garcia, F. J. et al. Single-cell dissection of the human brain vasculature. Nature 603, 893–899 (2022). · DOI · Paper page
  44. Tomassen, J. et al. Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: a monozygotic twin study. Alzheimers Dements 8, e12346 (2022).
  45. Tijms, B. M. et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-β 1–42 analysis results. Clin. Chem. 64, 576–585 (2018). · DOI · Paper page
  46. Mulder, C. et al. Amyloid-β(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 56, 248–253 (2010). · DOI · Paper page
  47. Ingala, S. et al. Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort. Alzheimers Dement 17, 1189–1204 (2021). · DOI
  48. Willemse, E. A. J. et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: the ABIDE project. Alzheimers Dement. 10, 563–572 (2018).
  49. Wesenhagen, K. E. J. et al. P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. Alzheimers Res. Ther. 14, 95 (2022). · DOI
  50. Dicks, E. et al. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol. Aging 61, 198–206 (2018). · DOI
  51. Legdeur, N. et al. Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60–102 years. J. Gerontol. A Biol. Sci. Med. Sci 75, 1609–1617 (2020). · DOI
  52. Lorenzini, L. et al. The Open-Access European Prevention of Alzheimer’s Dementia (EPAD) MRI dataset and processing workflow. Neuroimage Clin. 35, 103106 (2022). · DOI
  53. Plubell, D. L. et al. Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue. Mol. Cell. Proteomics 16, 873–890 (2017). · DOI · Paper page
  54. Rouillard, A. D. et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database 2016, baw100 (2016). · DOI · Paper page
  55. Otero-Garcia, M. et al. Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer’s disease. Neuron 110, 2929–2948 (2022). · DOI · Paper page
  56. Modeste, E. S. et al. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease. Mol. Neurodegener. 18, 48 (2023). · DOI
  57. Dammer, E. B. et al. Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers Res. Ther. 14, 174 (2022). · DOI · Paper page

Cited by

See all 202

Metadata

Authors
Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E. J., Lorenzini, L., Vermunt, L., Venkatraghavan, V., Tesi, N., Tomassen, J., den Braber, A., Goossens, J., Vanmechelen, E., Barkhof, F., Pijnenburg, Y. A. L., van der Flier, W. M., Teunissen, C. E., Berven, F. S., & Visser, P. J.
Venue
Nature Aging
Published
2024-01-09
Volume
4
Issue
1
Pages
33-47
ISSN
2662-8465 (ISSN-L)
OpenAlex
W4390706250
Cited by
202
References
60
FWCI
48.49
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • ZonMw (733050824)
  • the Dutch L’Óreal-UNESCO fellowship 2022 for women in science

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles. https://app.cochat.ai/papers/10.1038/s43587-023-00550-7
The paper
Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E. J., Lorenzini, L., Vermunt, L., Venkatraghavan, V., Tesi, N., Tomassen, J., den Braber, A., Goossens, J., Vanmechelen, E., Barkhof, F., Pijnenburg, Y. A. L., van der Flier, W. M., Teunissen, C. E., . . . Visser, P. J. (2024). Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles. Nature Aging. https://doi.org/10.1038/s43587-023-00550-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.